Centiva Capital, LP Keros Therapeutics, Inc. Put Options Transaction History
Centiva Capital, LP
- $3.13 Billion
- Q1 2025
Put Options
1 transactions
Others Institutions Holding KROS
# of Institutions
178Shares Held
36.3MCall Options Held
938KPut Options Held
1.39M-
Nuveen, LLC Charlotte, NC3.95MShares$55.4 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.6MShares$36.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.57MShares$36 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.51MShares$35.3 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA2MShares$28.1 Million3.97% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $361M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...